Conditions: Juvenile Idiopathic Arthritis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 41
Healthy volunteers: no

Brief summary:
This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment is 104 weeks.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: RoActemra/Actemra (tocilizumab)
Intervention descriptions: intervention 1: Tocilizumab 8 mg/kg every 4 weeks for 104 weeks

Protocol document: